nearly $60 million to seven other academic teams working on what’s called pancoronavirus vaccine development, which has similar goals. Four groups receiving support from either CEPI or NIAID toldthat long-existing difficulties obtaining comparator vaccines has slowed their progress. “The acquisition of those direct comparators has been very difficult and challenging,” says In-Kyu Yoon, a CEPI director.
The original doses of the Pfizer and Modern vaccines, which contain the surface protein from the initial strain of SARS-CoV-2, are of limited value as comparators: The two companies now make “bivalent” products that mix in a surface protein from the Omicron variant. But they, too, are locked up under the government purchase agreements.
PrEP4All, a nonprofit that advocates for improved public health responses to the COVID-19 pandemic, in April published
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Carscoop - 🏆 306. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: CNBC - 🏆 12. / 72 Read more »